The pioneering science behind VaxEquity
RNA therapeutics have emerged as a new modality for combating serious infections. Find out more about the science behind our next-generation RNA platform.
Science
Pioneering next generation RNA therapeutics & vaccines
VaxEquity is a UK biotechnology company developing next generation self-amplifying RNA and mRNA therapeutics and vaccines.
Our proprietary RNA platform is designed to modulate the innate immune response to enable higher and longer protein expression allowing lower doses and expanding the potential of RNA for therapeutics as well as vaccines.
Technology platform